Drug Trial Radar · NCT02169557
Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study
Last checked: Nov 20, 2026Latest source record: Jun 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
230
Actual
Start
Apr 30, 2014
Primary completion
Oct 9, 2016
Study completion Apr 25, 2017
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the treatment success of fexinidazole, at one year follow-up visit, in HAT stage 1 and early stage 2 patients.
Conditions
- Human African Trypanosomiasis (HAT)
Interventions
FexinidazoleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Outcome (success or failure) at the test of cure (ToC) visit 12 months after the end of treatment (EOT).Time frame: 12 months after end of treatment (day 11)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Kinshasa, Democratic Republic of the Congo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.